GE Healthcare has signed an R&D deal with ImaginAb to develop new PET radiopharmaceuticals based on ImaginAb's antibody fragment technology.
The companies launched the agreement with an initial exclusive collaboration around a novel cardiovascular target.
In other news, ImaginAb announced that it has been invited to join KeyMarker, a consortium of Belgian academic scientists and biotech companies working on the discovery of new diagnostic and therapeutic targets for diabetes. The consortium was established under the framework of BioWin, the health competitiveness cluster of the Walloon region in Belgium.
KeyMarker is being coordinated by IBA Molecular with Eurogentec and TraSis as industrial partners. Based on new biomarkers discovered at Université Libre de Bruxelles (ULB), the consortium's mission is to develop new targets to monitor and modulate beta cell depletion in adult-onset diabetes.
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
